156 related articles for article (PubMed ID: 25582738)
1. Quality of Life in Platinum-Sensitive Recurrent Ovarian Cancer: Chemotherapy Versus Surgery Plus Chemotherapy.
Plotti F; Scaletta G; Aloisi A; Luvero D; Capriglione S; Miranda A; Montera R; De Cicco Nardone C; Terranova C; Angioli R
Ann Surg Oncol; 2015 Jul; 22(7):2387-94. PubMed ID: 25582738
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Petrillo M; De Iaco P; Cianci S; Perrone M; Costantini B; Ronsini C; Scambia G; Fagotti A
Ann Surg Oncol; 2016 May; 23(5):1660-5. PubMed ID: 26714958
[TBL] [Abstract][Full Text] [Related]
3. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study.
Spiliotis J; Halkia E; Lianos E; Kalantzi N; Grivas A; Efstathiou E; Giassas S
Ann Surg Oncol; 2015 May; 22(5):1570-5. PubMed ID: 25391263
[TBL] [Abstract][Full Text] [Related]
4. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
[TBL] [Abstract][Full Text] [Related]
5. Does extensive upper abdomen surgery during primary cytoreduction impact on long-term quality of life?
Angioli R; Plotti F; Aloisi A; Capriglione S; Terranova C; Ricciardi R; Montera R; Zullo MA; Rasi V; Benedetti-Panici P
Int J Gynecol Cancer; 2013 Mar; 23(3):442-7. PubMed ID: 23429485
[TBL] [Abstract][Full Text] [Related]
6. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
7. Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer.
Felsinger M; Minar L; Weinberger V; Rovny I; Zlamal F; Bienertova-Vasku J
Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():154-160. PubMed ID: 29957400
[TBL] [Abstract][Full Text] [Related]
8. Oncologic Concerns regarding Laparoscopic Cytoreductive Surgery in Patients with Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy.
Favero G; Macerox N; Pfiffer T; Köhler C; da Costa Miranda V; Estevez Diz Mdel P; Fukushima JT; Baracat EC; Carvalho JP
Oncology; 2015; 89(3):159-66. PubMed ID: 25968072
[TBL] [Abstract][Full Text] [Related]
9. Peritoneal Surface Disease Severity Score (PSDSS), AGO-score and TIAN model in patients with platinum-sensitive recurrent ovarian cancer treated by cytoreductive surgery plus HIPEC.
Gómez-Ruiz ÁJ; González-Gil A; Gil J; Navarro-Barrios Á; Alconchel F; Gil E; Martínez J; Nieto A; Barceló F; Cascales-Campos PA
Clin Exp Metastasis; 2019 Oct; 36(5):433-439. PubMed ID: 31270731
[TBL] [Abstract][Full Text] [Related]
10. The Value of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer and Application of a Prognostic Score.
da Costa AA; Valadares CV; Mantoan H; Saito A; Salvadori MM; Guimarães AP; Sanches SM; Achatz MI; Baiocchi G
Int J Gynecol Cancer; 2016 Mar; 26(3):449-55. PubMed ID: 26825830
[TBL] [Abstract][Full Text] [Related]
11. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
12. Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients- a case-control study.
Safra T; Grisaru D; Inbar M; Abu-Abeid S; Dayan D; Matceyevsky D; Weizman A; Klausner JM
J Surg Oncol; 2014 Nov; 110(6):661-5. PubMed ID: 24962381
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: a retrospective study of 108 cases.
Classe JM; Jaffre I; Frenel JS; Bordes V; Dejode M; Dravet F; Ferron G; Marchal F; Rigaud DB; Loussouarn D; Campion L
Eur J Surg Oncol; 2011 Nov; 37(11):971-7. PubMed ID: 21944959
[TBL] [Abstract][Full Text] [Related]
14. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery.
Stoeckle E; Bourdarias L; Guyon F; Croce S; Brouste V; Thomas L; Floquet A
Ann Surg Oncol; 2014 Feb; 21(2):629-36. PubMed ID: 24052318
[TBL] [Abstract][Full Text] [Related]
15. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer.
Cascales-Campos PA; Gil J; Gil E; Feliciangeli E; González-Gil A; Parrilla JJ; Parrilla P
Ann Surg Oncol; 2014 Jul; 21(7):2383-9. PubMed ID: 24599409
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer.
Gockley A; Melamed A; Cronin A; Bookman MA; Burger RA; Cristae MC; Griggs JJ; Mantia-Smaldone G; Matulonis UA; Meyer LA; Niland J; O'Malley DM; Wright AA
Am J Obstet Gynecol; 2019 Dec; 221(6):625.e1-625.e14. PubMed ID: 31207237
[TBL] [Abstract][Full Text] [Related]
17. Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer.
Ceelen WP; Van Nieuwenhove Y; Van Belle S; Denys H; Pattyn P
Ann Surg Oncol; 2012 Jul; 19(7):2352-9. PubMed ID: 20039210
[TBL] [Abstract][Full Text] [Related]
18. Survival benefit of hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer: a multi-institutional case control study.
Le Brun JF; Campion L; Berton-Rigaud D; Lorimier G; Marchal F; Ferron G; Oger AS; Dravet F; Jaffre I; Classe JM
Ann Surg Oncol; 2014 Oct; 21(11):3621-7. PubMed ID: 24819120
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of recurrent ovarian cancer--a retrospective study].
Tkácová M; Belohorská B; Sevcíková K; Hel'pianska L; Ondrus D; Ondrusová M; Spánik S
Klin Onkol; 2010; 23(2):115-23. PubMed ID: 20465091
[TBL] [Abstract][Full Text] [Related]
20. The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: a multicenter retrospective Italian study.
Gadducci A; Cosio S; Zola P; Sostegni B; Ferrero AM; Teti G; Cristofani R; Sartori E
Gynecol Oncol; 2010 Mar; 116(3):358-63. PubMed ID: 19954826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
